Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

PCT - WORLD PATENTS IN SKIN CARE ACTIVES PUBLISHED IN 2008




CURRENT CONCENTRATION SYSTEM AND METHOD FOR ELECTROKINETIC DELIVERY OF MEDICAMENTS

(WO2008157485) 24.12.2008 A61N 1/30 TRANSPORT PHARMACEUTICALS, INC.
An electrokinetic apparatus to apply medicament to a treatment site of a mammalian user, the apparatus including: a flux concentrator including an active electrode and a counter electrode adapted to be applied to the surface of a toenail or fingernail of the user, and a medicament matrix adjacent the active electrode and arranged to be sandwiched between the active electrode and nail.


METHOD AND SYSTEM FOR MITIGATING CURRENT CONCENTRATION IN ELECTROKINETIC DRUG DELIVERY

(WO2008157481) 24.12.2008 A61N 1/30 TRANSPORT PHARMACEUTICALS, INC.
An electrokinetic apparatus to apply medicament to a treatment site of a mammalian user, the apparatus including: a segmented active electrode; a medicament matrix having one side abutting the segmented active electrode and another side adapted to contact a surface of skin over the treatment site, wherein the matrix includes at least one current direction barrier suppressing transverse current flow through the matrix.


TOPICAL COMPOSITION FOR TREATING PAIN

(WO2008156646) 24.12.2008 A61K 31/01 XVASIVE, INC.
Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as 'lipophilic vehicle' or 'LV' and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of an ointment, cream, gel, lotion, spray, foam, paste, patch, suspension or dispersion. In the preferred embodiment, the formulation is a gel. The LV may contain a penetration enhancer, most preferably one with membrane disruptive properties. The formulation may be applied to or impregnated into a gauze, wrap, bandage, cotton-tipped stick, adhesive bandage strip, or other support wrap or medical bandage or wound cover. For exa...


ALDOSTERONE INDUCED ELASTIN PRODUCTION

(WO2008154389) 18.12.2008 A61K 31/00 HUMAN MATRIX SCIENCES LLC
Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.


TOPICAL POLOXAMER FORMULATIONS FOR ENHANCING MICROVASCULAR FLOW: COMPOSITIONS AND USES THEREOF

(WO2008154368) 18.12.2008 A61K 9/14 UNIVERSITY OF VIRGINIA PATENT FOUNDATION
This invention relates to therapeutic compositions comprising a surface active copolymer, such as poloxamer-188, in an amount effective to enhance microvascular blood flow and/or inflammation in injured skin or other tissue, and methods of using the therapeutic compositions of the invention to inhibit decreased blood flow associated with an injury, disease, or disorder.


METHOD AND COMPOSITION FOR PROVIDING CONTROLLED DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES

(WO2008154294) 18.12.2008 A61K 47/48 UNICITY INTERNATIONAL, INC.
A method of providing controlled release of a biologically active substance within a subject's digestive system. The biologically active substance is administered concurrently with one or more soluble fibers in an oral dosage unit. The soluble fibers interact with the biologically active substance within the subject's digestive system to moderate and control the release of the biologically active substances in the subject's bloodstream. This provides more constant blood concentrations of the biologically active substances. The amount of soluble fibers in the oral dosage unit is greater than 40% by weight, and in some cases greater than 50% by weight of the oral dosage unit. The oral dosage unit typically contains from about 1 to 15g of solu...


TRANSDERMAL MEDICAMENT PATCH AND ACTIVE ELECTRODE FOR SAME

(WO2008153931) 18.12.2008 A61B 5/04 ACTIVATEK, INC.
A transdermal medicament patch ( 18,0168) includes a substrate(32, 172) having a therapeutic face (40, 180) configured for disposition against the skin (102), an adhesive on the therapeutic face (40, 180), a planar medicament matrix (46, 188) covering a portion of the therapeutic face (46,188), and a release liner (41, 182) covering the portion of therapeutic face (40, 180) not obscured by the medicament matrix (46, 188). An aperture (44, 186) through the release liner (41, 182) affords access to the medicament matrix (46, 188). An active electrode (54, 110, 120, 130, 140, 150, 210, 230, 250, 270, 290) positioned between the medicament matrix (46, 188) and the therapeutic face (40, 180) includes an electrically conductive backing layer (56,...


COMPOSITIONS WITH MODULATING AGENTS

(WO2008152444) 18.12.2008 None FOAMIX LTD.
The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless compostition and foam.


COSMETIC USE OF ACTIVE AGENTS FOR STIMULATING THE EXPRESSION OF FN3K AND/OR FN3K RP TO IMPROVE THE SKIN'S BARRIER FUNCTION

(WO2008151891) 18.12.2008 A61K 8/97 CHANEL PARFUMS BEAUTE
The present invention relates to a cosmetic process for caring for human skin, which is intended for preventing or combating the cutaneous signs resulting from non- pathological impairment of the barrier function, comprising the topical application to the skin of a composition containing at least one active agent for stimulating the expression of FN3K and/or FN3K RP. The invention also relates to the use of this active agent for preventing or combating the cutaneous signs resulting from non-pathological impairment of the barrier function.


USE OF ACTIVE AGENTS FOR STIMULATING THE EXPRESSION OF FN3K AND/OR FN3K RP FOR COMBATING AGEING OF THE SKIN

(WO2008151890) 18.12.2008 A61K 8/97 CHANEL PARFUMS BEAUTE
The present invention relates to a cosmetic process for caring for human skin, which is intended for preventing and/or combating at least one sign of ageing of the skin or the 'orange peel' appearance of the skin, comprising the topical application to the skin of a composition containing at least one active agent for stimulating the expression of FN3K and/or FN3K RP. The invention also relates to the use of this active agent for preventing and/or combating at least one sign of ageing of the skin or the 'orange peel' appearance of the skin associated with cellulite.


A PHARMACEUTICAL COMPOSITION

(WO2008001099) 31.12.2008 A61K 9/02 DRUG DELIVERY SOLUTIONS LIMITED
A pharmaceutical composition comprising a moulded body of a polymer matrix, said polymer matrix comprising at least one polyaphron dispersion and at least one pharmaceutically active agent dispersed therein.


TOPICAL COMPOSITIONS COMPRISING A MACROMOLECULE AND METHODS OF USING SAME

(WO2008150929) 11.12.2008 A61K 38/29 MANHATTAN PHARMACEUTICALS, INC.
Compositions, including those in which the active ingredient or agent is stable and capable of penetrating the sites of topical application are provided. The compositions can include a macromolecule, for example, a parathyroid hormone (PTH), a PTH-like hypercalcemic factor (CFF) or biologically active variant of a PTH or CFF in a vehicle comprising a polymer or cationic liposome. The compositions can also include other substances that further promote the stability of the active agent (e.g., buffers, antioxidants or carbohydrates). Also provided are methods for using the compositions for treatment of skin disorders (e.g., hyperproliferative skin disorders, including, but not limited to, for example, psoriasis, acne, rosacea or acne.)


MC-1 R, MC-2 R, AND Á OPIOID RECEPTORS MODULATION

(WO2008148892) 11.12.2008 A61K 36/14 BASF BEAUTY CARE SOLUTIONS FRANCE SAS
The invention concerns active substances modulating the expression of the receptors of the products of the POMC gene (MC-IR, MC-2R, and the ? opioid receptor), and possibly modulating the expression of POMC in cutaneous cells, notably to modulate the proliferation and differentiation of epidermal cells in order to re-epithelial, maintain innervation, irrigate the skin, or restore normal pigmentation, or to fight against aging, or to modulate pigmentation independently or not of cutaneous aging. The invention also concerns a method of screening such active substances.


MC-1R, MC-2R, AND/OR Á OPIOID RECEPTORS STIMULATION

(WO2008148891) 11.12.2008 A61K 8/97 BASF BEAUTY CARE SOLUTIONS FRANCE SAS
The invention concerns active substances modulating the expression of the receptors of the products of the POMC gene (MC-IR, MC-2R, and the ? opioid receptor), and possibly modulating the expression of POMC in cutaneous cells, notably to modulate the proliferation and differentiation of epidermal cells in order to re-epithelial, maintain innervation, irrigate the skin, or to fight against aging, or to modulate pigmentation independently or not of cutaneous aging. The invention also concerns a method of screening such active substances.


INTRANUCLEAR PROTEIN TRANSDUCTION THROUGH A NUCLEOSIDE SALVAGE PATHWAY

(WO2008148063) 04.12.2008 C07K 17/00 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conju...


COMPOSITION OF SKIN EXTERNAL APPLICATION CONTAINING GINSENG FRUIT EXTRACTS

(WO2008147148) 04.12.2008 A23L 1/307 AMOREPACIFIC CORPORATION
Disclosed herein is a. skin external composition containing ginseng berry extract. More specifically, disclosed is a skin external composition, which contains, as an active ingredient, ginseng berry extract having the specific components and compositions, among the above- ground parts of ginseng, and thus promotes the production of collagen in the skin, shows an MMP-I inhibitory effect and, at the same time, has skin-aging inhibitory and wrinkle-reducing effects, resulting from antioxidant effects and DNA damage-protecting effects. Also disclosed is a skin external composition, which contains, as an active ingredient, ginseng berry extract, which has a skin whitening effect resulting from the effects of inhibiting melanin production and red...


COMPOSITION FOR TREATMENT OF ISCHEMIC HEART DISEASE, FACILITATION OF BLOOD CIRCULATION AND ANGIOGENESIS, IMPROVING SKIN BEAUTY, IMPROVING MALE SEXUAL FUNCTION CONTAINING GINSENG BERRY EXTRACT

(WO2008147111) 04.12.2008 A61K 36/258 AMOREPACIFIC CORPORATION
A composition containing ginseng berry extract as active ingredient is for facilitation of blood circulation, for prevention of vascular aging, for treatment of vascular inflammation, for facilitation of angiogenesis, for treatment of ischemic heart disease, for improvement and treatment of local blood circulation insufficiency, for improvement of skin beauty and for improvement of male sexual function,. More particularly, the compositions containing ginseng berry extract as active ingredient facilitate nitric oxide (NO) generation in endothelial cells, improve viability of endothelial cells, and facilitate angiogenesis through increased mobility of endothelial cells and vascular tube formation; provide antioxidative effect, facilitate bios...


ANTI-WRINKLE COMPOSITION FOR EXTERNAL APPLICATIONS TO THE SKIN CONTAINING BIFLAVONOID DERIVATIVES

(WO2008147022) 04.12.2008 A61K 8/49 AMOREPACIFIC CORPORATION
The present invention relates to a cosmetic composition for improving skin wrinkles, which contains biflavonoid derivatives as an active ingredient. The cosmetic composition containing the biflavonoid derivatives of the present invention not only is safe for application on the skin without side-effects but also improves wrinkles caused by UV through procollagen production and MMP-I inhibition.


A PHARMACEUTICAL COMPOSITION CONTAINING DAURINOL FOR THE PREVENTION AND TREATMENT OF CANCERS

(WO2008146989) 04.12.2008 A61K 31/343 KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising daurinol as an active ingredient, more precisely a pharmaceutical composition for the prevention and treatment of cancer comprising daurinol isolated from the medicinal plant of Mongolia, Haplophyllum dauricum or Haplophyllum cappadocicum, as an active ingredient. Daurinol can selectively block the S phase of cancer cell cycle to disturb the cycle and induce apoptosis stepwise, resulting in anticancer effect. Therefore, daurinol of the present invention can be used as a positive control chemical in the research and development field of cancer biology especially for cancer therapy and prevention. Daurinol also can be a promisin...


COSMETIC COMPOSITION COMPRISING AN ACTIVE AGENT CAPABLE OF STIMULATING TENSIN 1 EXPRESSION

(WO2008145692) 04.12.2008 A61K 8/97 CHANEL PARFUMS BEAUTE
The present invention relates to a cosmetic composition containing: (a) at least one active agent capable of stimulating tensin 1 expression, and (b) at least one active agent for stimulating the synthesis of extracellular macromolecules in tne dermis, and in particular of fibro¤Çectin. It also pertains to a skincare process intended to prevent and/or treat at least one cutaneous sign of aging, comprising the topical application to the s╬║in of this composition. Finally, it relates to a specific extract of elemi or of Canariuin indicum L. or of Canarium luzonicum or of Canarium commune, able to stimulate tensin 1 expression, and to a cosmetic composition containing said extract.


USE OF HERBAL COMPOSITIONS IN THE PROTECTION AND ENHANCEMENT OF EXTRACELLULAR MATRIX COMPONENTS

(WO2008142619) 27.11.2008 A61K 36/23 IZUN PHARMACEUTICALS CORPORATION
The present invention provides a method for treating and/or preventing degeneration of collagen and/or other extracellular matrix components in a mammalian subject, wherein said method comprises administering to said subject a herbal composition comprising an extract of Centella asiatica and/or an extract of Sambucus nigra as the active component (s).


TOPICAL COMPOSITIONS CONTAINING MAGALDRATE

(WO2008142569) 27.11.2008 None DIFASS S.A.
Disclosed are topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients.


SKIN TREATMENT COMPOSITIONS AND METHODS

(WO2008140673) 20.11.2008 A61K 8/02 SYTHEON LTD.
A skin treatment composition or cosmetic product comprising a) two or more active components, namely, at least one dermatological acid and at least one meroterpene and b) a dermatologically acceptable carrier.


SKIN CARE COMPOSITION

(WO2008139182) 20.11.2008 A61P 17/10 JONES, Frances, Prenna
A multi-tasking cosmetic composition comprising synergistic combinations of active agents from natural sources comprises a suitable carrier and a plurality of active ingredients including: at least one exfoliant; at least one astringent; at least one antioxidant; and at least one moisturiser. The at least one exfoliant may comprise salicylic acid and glycolic acid, alternatively, the at least one exfoliant may comprise salicylic acid lactic acid and lactobionic acid. The at least one astringent may comprise Hamamelis virginiana extract (Witch Hazel). The at least one anti-oxidant may comprise Chrysanthemum parthenium extract (Feverfew). The cosmetic composition may be formulated as a skin tonic.


TRANSDERMAL AND TRANSMUCOSAL DRUG DELIVERY ENHANCERS

(WO2008139170) 20.11.2008 A61K 9/70 SINCLAIR PHARMACEUTICALS LIMITED
Compounds of Formula (I) have been found to be effective transdermal and transmucosal penetration enhancers. A composition of the invention therefore comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmacologically active agent wherein: X is O or CH - R5 R5 is branched or straight C5-C14 alkyl, especially 2-propylpentyl; and when X is O then R1, R2, R3 and R4 each independently is H or at most two of them being branched or straight C4 - C16 alkyl, the remaining being H, A is (CH2)2-6 R6 is OH; and when X is CH - R5 then R1, R2, R3 and R4 is H; A is (CH)2-6 or CO(CH2)6-14; R6 is CH3 or OH; and N in formula (I) optionally being quaternized, including racemic and enantiomeric forms.


NEW PHARMACEUTICAL COMPOSITIONS COMPRISING DIIODOTHYRONINE AND THEIR THERAPEUTIC USE

(WO2008138993) 20.11.2008 A61K 31/198 UNIVERSITE JOSEPH FOURIER
The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3,5-diiodothyronine (3,5-T2), 3',3- diiodothyronine (3',3-T2), 3',5-diiodothyronine (3 ',5-T2), 3 '-iodothyronine (3'-T), 3- iodothyronine (3-T) or 5 -iodothyronine (5-T), in association with a pharmaceutically acceptable vehicle.


GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS

(WO2008138393) 20.11.2008 A61K 8/04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
It is described a gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles.


CLEANSING AND PERSONAL CARE ARTICLE

(WO2008137157) 13.11.2008 C11D 3/00 SPONGEABLES, LLC
A single- or multiple-use cleansing or personal care article comprising (i) a flexible, three-dimensional, water-absorbent substrate material comprising a cavity for accepting an electronic device within a waterproof housing, wherein the water-absorbent substrate is comprised of a web of substantially water-insoluble fibers and (ii) an electronic device within a waterproof housing comprised of one or more of a light-emitting device, a sound-emitting device, or an electromechanical vibrating device or a waterproof metered dispenser and either or both of (iii) a pourable soap impregnated into the water- absorbent material in an amount sufficient to produce foam in water having a di- or trivalent cationic salts present at a concentration of at...


COMBINED USE OF EGF PATHWAY INHIBITORS AND DIFFERENTIATION PROMOTING COMPOUNDS

(WO2008132608) 06.11.2008 A61K 31/727 UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
The present invention is a pharmaceutical composition and method for its use in the treatment of chronic inflammatory skin diseases such as psoriasis. The pharmaceutical composition combines an inhibitor of the EGF receptor signaling pathway with an agent that promotes cell differentiation. This pharmaceutical composition may be administered orally or topically, and results in superior treatment of chronic inflammatory skin diseases than methods presently in use.


A SINGLE USE APPLICATOR CARTRIDGE FOR AN ELECTROKINETIC DELIVERY SYSTEM AND METHOD FOR SELF ADMINISTRATION OF MEDICAMENTS

(WO2008131205) 30.10.2008 A61N 1/30 TRANSPORT PHARMACEUTICALS, INC.
An applicator cartridge for use with a device for electrokinetically delivering a medicament to a treatment site, the cartridge including: an applicator head including an active electrode, and a conductive path extending between a pair of electrical contacts, wherein the electrical contacts electrically engage respective contacts on the device when the cartridge is inserted into the device; a matrix support surface of said applicator head adjacent the active electrode; a matrix attached to the matrix support surface and in contact with the active electrode, the matrix having an exposed surface adapted to be applied to the treatment site; a medicament or a medicament and an electrically conductive carrier carried by said matrix; a removable ...


CURRENT DENSITY DETECTION AND CONTROL SYSTEM AND METHOD FOR AN ELECTROKINETIC DELIVERY OF MEDICAMENTS

(WO2008131072) 30.10.2008 A61N 1/30 TRANSPORT PHARMACEUTICALS, INC.
An apparatus to monitor current density in the application of medicament to a treatment site of a mammalian user of a electrokinetic device including: an applicator cartridge including an active electrode, a matrix carrying a medicament or a medicament and an electrically conductive carrier; a device including an electrical power source connectable to the active electrode, a counter electrode, and an electronic circuit configured to control the application of electrical current through the active electrode to establish a conductive path extending from the power source, through the active electrode, matrix, the treatment site, the user and the counter electrode electrically connected to the power source, and an array of contacts monitoring c...


NANOPARTICLE-COATED CAPSULE FORMULATION FOR DERMAL DRUG DELIVERY

(WO2008128292) 30.10.2008 A61K 9/14 UNIVERSITY OF SOUTH AUSTRALIA
A method and formulation for the delivery of an active substance to the skin (epidermis, including the stratum corneum and viable epidermis, and dermis) of a subject. The formulation comprises oil-based or aqueous droplets comprising the active substance within a coating of nanoparticles, particularly silica nanoparticles. The active substance may be suitable for the treatment of a disease or condition which is localised, or at least partially localised, to the skin (eg skin cancer, psoriasis, eczema, infections including bacterial and fungal infections, acne, dermatitis, inflammation, and rheumatoid arthritis).


FUSION PROTEINS OF COLLAGEN-BINDING DOMAIN AND PARATHYROID HORMONE

(WO2008124166) 16.10.2008 C12N 15/09 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen- binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.


ANTIPERSPIRANT/DEODORANT COMPOSITIONS AND METHODS

(WO2008118910) 02.10.2008 A61L 9/01 JOSHI, Vijay, K.
An aqueous based antiperspirant/deodorant composition comprising (a) an antiperspirant active ingredient; (b) at least one water absorbing polymer pretreated with a non-aqueous polar solvent; and (c) water, wherein the pretreated water absorbing polymer inhibits the water absorbing properties of the polymer in the aqueous based composition prior to application to the skin.


SUSTAINED-RELEASE COMPOSITION

(WO2008115961) 25.09.2008 A61K 8/11 DOW GLOBAL TECHNOLOGIES INC.
A composition which comprises (A) a plurality of cross-linked polymer particles, said polymer being the polymerization product of at least two monomer units selected from the group consisting of monoalkenyl aromatic compounds, alkyl esters derived from a saturated alcohol and acrylic or methacrylic acid, and vinyl esters of an aliphatic carboxylic acid; and said cross-linked polymer particles being loaded with (B) an active ingredient, the weight ratio of the active ingredient (B) to the polymer particles (A) being from 0.05 to 50 : 1, is useful to release the active ingredient over an extended period of time while controlling sebum on skin and hair.


NOVEL USE OF EC-SOD AND METHOD FOR PREPARING THEREOF

(WO2008115039) 25.09.2008 A61K 38/16 INDUSTRY ACADEMIC COOPERATION FOUNDATION, THE CATHOLIC UNIVERSITY OF KOREA
The present invention relates to compositions for preventing or treating angiogenesis-mediated diseases or allergic diseases which contain, as an active ingredient, an EC-SOD protein or a vector having a polynucleotide encoding thereof. The EC-SOD protein or the vector having a polynucleotide encoding the EC-SOD protein has the effect on inhibiting angiogenesis by inhibiting the expression of VEGF and MMP-9 which induce angiogenesis. Therefore, the EC-SOD protein or the vector may be useful for preventing or treating angiogenesis-mediated diseases. And the EC-SOD protein or the vector having a polynucleotide encoding said EC-SOD protein also has the effect on inhibiting over- differentiation of Th2 cells which cause allergic diseases, inhib...


COMPOSITION HAVING AN INHIBITORY ACTIVITY ON 5 ╬▒-REDUCTASE

(WO2008114141) 25.09.2008 None GIULIANI S.P.A.
The present invention relates to the use of selected active principles of a natural origin in substitution of extract from Boehmeria Nipononivea for regulating the trophism of hair follicles and the production of sebum on the skin and its use in alopecia, with considerable practical advantages and with respect to the safety- profile. The composition of the invention is based on an association of omega 6 polyunsaturated acids and rutin in a pharmaceutically acceptable carrier.


METHODS, PROCESSES AND COMPOSITIONS COMPRISING THE PROTEIN CALMODULIN (CAM) FOR TREATMENT OF DAMAGED OR AGEING SKIN, AND/OR HAIR LOSS

(WO2008114082) 25.09.2008 A61K 38/16 TIPPENS, Dorr, Felt
The invention relates to compositions comprising the calcium binding protein, calmodulin (CaM), and the use of this protein additive in compositions suitable for topical application for the maintenance and development of healthy skin; for improving the aesthetic appearance of skin; for treating fine lines, and/or wrinkles, and/or age spots, and/or minor wounds and burns, and/or calloused skin - through its facilitation of natural healing processes initiated by disease, injury or aging; for enhancing hair growth; and as a cosmetic treatment process comprising application to the skin the compositions, preferably on a daily basis. The compositions may comprise, but not be limited to, UV blocking agents and/or penetration enhancers and/or one o...


PERSONAL CARE KIT HAVING SKIN CARE COMPOSITIONS WITH A READILY PERCEPTIBLE DIFFERENCE

(WO2008112964) 18.09.2008 A61K 8/02 THE PROCTER & GAMBLE COMPANY
A personal care kit comprises a first series of unit-dose packages containing a first skin care composition and a second series of unit-doses packages containing a second skin care composition, wherein the first skin care composition and the second skin care composition exhibit a readily perceptible difference. The readily perceptible difference may be a visible difference, a tactile difference, or an olfactory difference. The first and/or second skin care composition may comprise a skin care active. A method for using the personal care kit is also disclosed.


METHOD AND COMPOSITION FOR TREATING CANCER

(WO2008112565) 18.09.2008 A61K 9/14 MANGANARO, Anthony
A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or a human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.


POLYPHENOL COMPOUNDS WITH MODULATING NEUROTRANSMITTER RELEASE

(WO2008111796) 18.09.2008 A61K 31/35 SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
Disclosed is a composition for modulating the release of a neurotransmitter, which includes naturally extracted polyphenols as an active ingredient. The disclosed composition suppresses the formation of a SNARE complex, thereby modulating the release of a neurotransmitter, and thus can be used as a modulator for a reaction within a cell related to the SNARE complex. Such an inhibitor of the SNARE complex formation can be used as a composition for reducing wrinkles and relieving pain.


FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND RELATED AGENTS AND THEIR USES

(WO2008110872) 18.09.2008 A61K 9/00 FOAMIX LTD.
The present invention relates to a foamable therapeutic composition comprising: (a) a therapeutically effective concentration of at least one active agent selected from the group consisting of a channel agent, a cholinergic agent, and a nitric oxide donor; and (b) a foamable carrier comprising: i. about 50% to about 98% of a solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, and mixtures thereof; ii. 0% to about 48% of a secondary solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, a co-solvent, a penetration enhancer and mixtu...


DEPILATORY COMPOSITION

(WO2008110745) 18.09.2008 A61K 8/25 RECKITT BENCKISER (UK) LIMITED
A depilatory cream composition comprising, a depilatory active, an emollient selected from at least one of mineral oil, silicone oil and emollient esters, and a silicone wax, a talc and/or polyamide resin.


COSMETIC USE OF ORGANIC RESINATES

(WO2008110628) 18.09.2008 A61K 8/72 CHANEL PARFUMS BEAUTE
The present invention relates to a cosmetic method for releasing an active principle in a controlled fashion to uninjured skin, as a function of the ion content in or on skin, by exchange with said ions, in order to provide at least one cosmetic benefit to the skin, said method comprising applying onto skin a composition containing, in a cosmetically acceptable medium, at least one resinate including one organic ion-exchange resin and at least one ionizable cosmetic active principle bonded in noncovalent fashion to said resin.


COMPOSITION AND METHOD FOR TREATING PAPILLOMA VIRUS AND EQUINE SARCOIDS

(WO2008109401) 12.09.2008 A61K 38/47 SAINT SIMEON LDA
A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR ┬ž 1.72(b).


COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING ALPHA-BISABOLOL AS AN ACTIVE INGRDIENT

(WO2008105632) 04.09.2008 A61K 8/34 BIOSPECTRUM INC.
The present invention relates to a composition for improving skin condition comprising ╬▒-bisabolol as an active ingredient. ╬▒-Bisabolol used as an active ingredient has greater skin whitening effect inhibiting melanin synthesis by inhibiting intracellular tyrosinase activities compared to arbutin used as an existing skin whitening agent. In addition, ╬▒-bisabolol exhibits the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. Meanwhile, ╬▒-bisabolol indicates the improvement effects on UV-induced skin damage and the skin growth promotion or hair loss prevention. Therefore, ╬▒-bisabolol has the excellent improvemen...


COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING ALPHA-BISABOLOL AS AN ACTIVE INGRDIENT

(WO2008105632) 04.09.2008 A61K 8/34 BIOSPECTRUM INC.
The present invention relates to a composition for improving skin condition comprising ╬▒-bisabolol as an active ingredient. ╬▒-Bisabolol used as an active ingredient has greater skin whitening effect inhibiting melanin synthesis by inhibiting intracellular tyrosinase activities compared to arbutin used as an existing skin whitening agent. In addition, ╬▒-bisabolol exhibits the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. Meanwhile, ╬▒-bisabolol indicates the improvement effects on UV-induced skin damage and the skin growth promotion or hair loss prevention. Therefore, ╬▒-bisabolol has the excellent improvemen...


COSMETIC COMPOSITION FOR SKIN WHITENING COMPRISING ARCTIIN, ARCTIGENIN OR THE MIXTURE THEREOF AS ACTIVE INGREDIENT

(WO2008105605) 04.09.2008 A61K 8/49 COREANA COSMETICS, CO., LTD
Present Invention relates to a skin whitening cosmetic composition comprising arctiin, arctigenin or a mixture thereof as an active ingredient. The disclosed composition can control or inhibit the synthesis of melanin by acting on a melanin synthesis route of ╬▒-MSH secreted by UV, and thus show an excellent whitening effect compared to a conventional skin whitening cosmetic. Also, the composition has high formulation stability and low skin irritation.


EXTERNAL COMPOSITION FOR SKIN CONTAINING SCROPHULARIA BUERGERIANA MIQ. EXTRACT AND THE USE THEREOF FOR THE SKIN MOISTURIZING COSMETICS

(WO2008105579) 04.09.2008 A61K 8/97 AMOREPACIFIC CORPORATION
Disclosed herein is a skin external composition for alleviating dry skin symptoms, which contains an extract of Scrophularia buergeriana Miq. as a main component and further contains an extract of Poria cocos Wolf, as well as the use thereof for skin-moisturizing cosmetics. The composition contains, as active ingredients, the Scrophularia buergeriana Miq. extract and the Poria cocos Wolf extract, which are prepared by extracting each of Scrophularia buergeriana Miq. and Poria cocos Wolf using water, ethanol, methanol, hexane, ethyl acetate or butanol.


COMPOSITIONS AND/OR ARTICLES COMPRISING CYCLODEXTRIN COMPLEXING MATERIAL

(WO2008104954) 04.09.2008 A61F 13/15 THE PROCTER & GAMBLE COMPANY
Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of the plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 90%, so that the perceptibility of the first fragrance is minimized prior to its release; and a second fragrance material that is not complexed with the cyclodextrin and that is different from the first fragrance material,...


COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING CARVACROL AS AN ACTIVE INGREDIENT

(WO2008102998) 28.08.2008 A61K 31/11 BIOSPECTRUM INC.
The present invention relates to a composition for improving skin conditions comprising carvacrol as an active ingredient. Carvacrol used as an active ingredient, has lower cytotoxicity compared to retinol used as anti-wrinkle agents and exhibits the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. In addition, carvacrol exhibits the excellent anti-oxidation, skin growth promotion or hair loss prevention effects. In addition, the composition of this invention can be applied to cosmetic, pharmaceutical and food composition having no cytotoxicities and side effects.


COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING MATRINE OR ITS OXIDIZED DERIVATIVES

(WO2008102997) 28.08.2008 A61K 8/49 BIOSPECTRUM INC.
The present invention relates to a composition for improving skin conditions comprising matrine and oxymatrine as an active ingredient. Matrine and oxymatrine have lower cytotoxicity than retinol used as anti-wrinkle agents and exhibit the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. In addition, both matrine and oxymatrine exhibit the inhibition effect on melanin production by inhibiting intracellular tyrosinase activity, the improving effects of UV- induced skin damage and the skin growth promotion or hair loss prevention. Therefore, matrine and oxymatrine have the excellent improvement effects on skin condi...


TERBINAFINE FORMULATION

(WO2008102349) 28.08.2008 A61K 9/10 POWER PAPER LTD
The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and combinations thereof; and wherein substantially no alcohol is present.


SOLID PHARMACEUTICAL AND VACCINE DOSE

(WO2008102136) 28.08.2008 A61K 9/20 GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
An elongate body for parenteral injection at low velocity from a device is described. The body has at least one pointed end and comprises at least one active material. In addition, the body has a compressive strength of greater than or equal to 5 Newton and the pointed end has an included angle of between about 10-50┬░. A solid vaccine formulation for needle-free parenteral delivery, methods for making the body, packaging of the body and use of the body, packaging and suitable delivery device are also described.


INCREASED EFFECTIVENESS OF ALLYLAMINE DRUG COMPOUNDS

(WO2008097530) 14.08.2008 A61K 9/00 SUVANPRAKORN, Pichit
The invention is an increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of skin and skin appendages The allylamine active ingredient is prepared in an acidic environment, which alters the physiochemical properties of the active ingredient resulting in the ingredient having a positive charge The positive charge and enhancers used in the formula allo for increased penetration of the active ingredient through skin and skin appendages The positively charged active ingredients are eithe dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle The bead structure minimizes the molecular diffusion of the positively charged active ingredient and a catalytic species th...


HIGH EFFICIENCY SUNSCREEN COMPOSITION PARTICULARLY USEFUL FOR WIPES AND SPRAYS

(WO2008097223) 14.08.2008 A61K 8/26 AMCOL INTERNATIONAL CORPORATION
A sunscreen composition, either impregnating a wipe substrate or comprising a sunscreen spray, wherein the composition comprises an oil phase containing a UV-absorbing organic sunscreen active, said oil phase dispersed stably as emulsion droplets in a water phase that contains i) a booster for the sun protection factor (SPF), comprising a combination of water-dispersible particulate materials, one of which is smectite clay, and a water-soluble or water-dispersible phenolic polymer; and ii) a water-soluble or water-dispersible polymer having a weak acid group, a weight average molecular weight of 1, 000 - 100, 000 Dalton, and an anionic charge density of no less than 4 milliequivalent per gram of the polymer.


PHARMACEUTICAL COMPOSITIONS BASED ON A MICROEMULSION

(WO2008096351) 14.08.2008 A61K 9/00 NANODERMA LTD.
The invention provides a transdermal, transmucosal pharmaceutical composition suitable for substantially extra-vascular application of at least one biologically active substance to biological membranes of a mammal, comprising a pharmaceutical or cosmetic composition comprising propylene carbonate at least one oil or source of fatty acid or surfactant; and water; in combination with the at least one biologically active substance wherein the propylene carbonate is adapted to enhance the bioavailability of the at least one biologically active substance.


CONTROLLED RELEASE OF ACTIVES IN SKIN

(WO2008095144) 07.08.2008 A61K 9/14 RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Topical compositions are provided in which active compounds for topical delivery through the stratum corneum are complexed with nanospheres of a triblock copolymer having an A-B-A structure wherein each A end block is a water-soluble, hydrophilic and non-toxic polymer or oligomer; and the hydrophobic middle B block is a hydrophobic polymer or oligomer with the same or different repeating units having the structure according to formula:(I) wherein X is - C - R - C - or - C -; Z is between 2 and about 100, inclusive; R1 is CH=CH or (CH2),, wherein n is from 0 to 18, inclusive; R2 is selected from hydrogen and straight and branched alkyl, alkoxy, alkylaryl and alkoxyaryl groups containing up to 18 carbon atoms; and R is selected from a bond or...


HYDROGEL FORMULATIONS COMPRISING ACTIVE DRUGS FOR TREATING WOUNDS

(WO2008094002) 07.08.2008 A61K 9/70 TDS PHARM. CO., LTD.
The present invention relates to a hydrogel formulation for treating wounds comprising water, an active drug or salt thereof, a water soluble polymer and polyols. The present invention can effectively treat bacterial infections by continuously releasing the active drug, and improves wound healing by absorbing exudation.


COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING A PEROXIDE AND RETINOID

(WO2008093346) 07.08.2008 A61K 9/16 SOL-GEL TECHNOLOGIES LTD.
The invention relates to a composition for topical application comprising as an active ingredient a peroxide and a retinoid wherein one of said peroxide and retinoid is in the form of first microparticles comprising a solid particulate matter of the active ingredient coated by a metal oxide layer and the other of said peroxide and retinoid is present in an uncoated free form or in a coated form of the active ingredient. The invention further relates to method for treating a surface condition in a subject using said composition, a method for preparing a composition exhibiting improved stability, and a kit comprising: (a) a first composition comprising a peroxide as a first active ingredient; and (b) a second composition comprising a retinoid...


SHORT BIO-ACTIVE PEPTIDES FOR CELLULAR AND IMMUNOLOGICAL MODULATION

(WO2008085494) 17.07.2008 C07K 14/435 HELIX BIOMEDIX INC.
Peptides having four to fourteen residues are disclosed that possess biological activity. These peptides constitute short fragments of the peptide HB-107 (SEQ ID NO:1), which itself is a fragment of the antimicrobial protein cecropin B, and exhibit cell stimulatory, migratory and anti-inflammatory properties. As keratinocytes are especially sensitive to these effects, the disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-10...


COSMETIC COMPOSITION FOR PROTECTING SKIN AGAINST UV LIGHT AND WRINKLE IMPROVEMENT CONTAINING THE EXTRACT OF MAGNOLIA SIEBOLDII FLOWER EXTRACTS

(WO2008084923) 17.07.2008 A61K 8/97 COREANA COSMETICS, CO., LTD
Disclosed herein is a cosmetic composition for preventing photoaging, containing an extract of Magnolia sieboldii as an active ingredient. Also disclosed is a cosmetic composition for reducing skin wrinkles containing an extract of Magnolia sieboldii as an active ingredient. The extract of Magnolia sieboldii can protect the skin against UV lights and skin damage by suppressing skin cell death and cell DNA damage, and can reduce skin wrinkles by promoting the biosynthesis of collagen and suppressing the synthesis of collagenases. Also, the cosmetic composition containing the extract of Magnolia sieboldii has an excellent effect of inhibiting skin damage caused by UV lights, and an excellent effect of reducing skin wrinkles.


SPREADING IMPLEMENT

(WO2008083423) 17.07.2008 A61M 35/00 ACRUX DDS PTY LTD
This invention relates to an implement (1) for applying a volume of liquid to a treatment surface. The implement includes a support means (3) onto which is mounted a receptacle (2), the receptacle defining a reservoir space (4) which receives the liquid. The receptacle includes a wall (6) having a working surface that is used to spread the liquid over the treatment surface. The wall (6) is resiliently deformable so in use the working surface maintains contact with the treatment surface when spreading the liquid. The implement has a specific application in applying a transdermal lotion to the axilla area of the user. The invention also relates to a system for transdermal administration of a physiological active agent from a liquid compositio...


COMPOUNDS, COMPOSTIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINSTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A REYINOID

(WO2008083370) 10.07.2008 A61K 9/00 WISCONSIN ALUMNI RESEARCH FOUNDATION
Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-l╬▒-hydroxy-bishomopregnacalciferol, 19-nor- 26,27-dimethylene-20(S)-2-methylene-l╬▒,25-dihydroxyvitamin D3, 2-methylene-l╬▒,25- dihydroxy-( 17E)- 17(20)-dehydro- 19-nor-vitamin D3, 2-methylene- 19-nor-(24R)- 1 ╬▒,25- dihydroxyvitamin D2, 2-methylene-(20R,25S)-19,26-dinor-l╬▒,25-dihydroxyvitamin D3, 2- methylene- 19-nor- 1 ╬▒-hydroxy-pregnacalciferol, 1 ╬▒-hydroxy-2-methylene- 19-nor- homopregnacalciferol, (20R)- 1 ╬▒-hydroxy-2-methylene- 19...


COSMETIC COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF SKIN STRETCH MARKS

(WO2008080443) 10.07.2008 A61Q 19/08 LABO COSPROPHAR AG
The present invention relates to a cosmetic composition for the treatment and/or prevention of skin stretch marks based on the synergic association of a base formulation containing matrikine (s), rutin and Phaseolus extract, with one or more active principles of a natural origin selected from real aloe extract, vitamin E, sericin, Delesseria sanguinea extract, Saccharomices lysate, Chlorella alga extract, lipopeptide comprising the amino-acid sequence Lys-Thr-Thr-Lys-Ser.


PYRROLO [2,3-B] PYRIDINES AS KINASE MODULATORS

(WO2008079909) 03.07.2008 A61K 31/437 PLEXXIKON, INC.
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.


PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS

(WO2008079906) 03.07.2008 C07D 471/04 PLEXXIKON, INC.
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.


PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS

(WO2008079903) 03.07.2008 C07D 471/04 PLEXXIKON, INC.
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.


A NOVEL USE OF ANTIDEPRESSANT COMPOUNDS AND RELATED COMPOSITIONS

(WO2008078353) 03.07.2008 A61K 31/4525 MEDESTEA INTERNAZIONALE S.P.A.
What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals. For this purpose, the antidepressant can be formulated in a cosmetic preparation, a pharmaceutical composition, a medical device, or in the form of a culture medium, alone or in combination with a further active ingredient such as a proteolytic enzyme and/or a vitamin.


SKIN LIGHTENING COMPOSITION FOR HYPERPIGMENTED SKIN

(WO2008078154) 03.07.2008 A61K 8/60 ROMANO DEVELOPMENT INC.
An improved skin composition intended for topical application to skin for lightening hyperpigmented skin is provided. The subject composition is characterized by incorporation of at least one carbohydrate-based melanin inhibiting agent selected from bearberry extract, ascorbyl glucoside, rutin and arbutin into an ultra low molecular weight aminoglycan polymer gel. It has been found that the skin composition of the present invention possesses improved skin penetration and significantly enhances the depigmenting effect of the active agents.


UV ABSORBING COMPOSITIONS CONTAINING A PYRROLYLTRIAZINE

(WO2008067928) 12.06.2008 A61K 8/49 ISDIN S.A.
The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B), wherein the UV-absorbing active substance (A) is at least one pyrrolyltriazine compound of the general formula (I) which is defined as hereinafter and which has its absorption maximum ╬╗max in the range of UV-A or UV-B radiation, in combination with at least one UV-absorbing active substance (B), which has its absorption maximum ╬╗max(B) in the range of UV-A or UV-B radiation, preferably in such UV radiation range in which the ╬╗max(A) of UV-absorbing active substance (A) does not lie, and wherein the ratio of the molar extinction coefficient at ╬╗max [╬Á╬╗max(A)] of the UV-absorbing active substance (A) to the molar extinction coefficien...


ANTICANCER COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM

(WO2008066301) 05.06.2008 A61K 31/343 MD BIOALPHA CO., LTD.
Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a certain naphthoquinone-based compound or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient having therapeutic effects on prevention or treatment of i) cancer, or treatment of ii) bacterial, fungal or parasitic infectious diseases and/or iii) dermatological diseases.


COSMETIC COMPOSITIONS CONTAINING A SILOXANE- CONTAINING ARYLALKYL BENZOATE AMIDE DERIVATIVE; USE OF SAID DERIVATIVE AS SOLVENT IN OILS; NOVEL SILOXANE- CONTAINING ARYLALKYL BENZOATE AMIDE DERIVATIVES

(WO2008064979) 05.06.2008 A61K 8/58 L'OREAL
The invention relates to a composition comprising, in a cosmetically acceptable medium, at least one specific siloxane-containing arylalkyl benzoate amide derivative of formula (I) and more particularly to a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at least one low-solubility lipophilic active agent, in particular a low-solubility lipophilic organic screening agent, such as triazine derivatives, dibenzoylmethane derivatives or benzophenone derivatives. The present invention relates to the use of at least one specific siloxane-containing arylalkyl benzoate amide derivative of formula (I) in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase an...


PERSONAL CARE COMPOSITION

(WO2008063441) 29.05.2008 A61K 8/37 THE PROCTER & GAMBLE COMPANY
Personal care composition comprising at least one skin care active selected from the group consisting of acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tributyl citrate, acetyl triethyl citrate, acetyl tyrosine, adipic acid, alanine, arginine, arginine glutamate, benzophenone-3, camphor, gluconolactone, glucose, glycine, histidine hydrochloride, hydroxyproline, maltitol, phenylalanine, succinic acid, buffered lactic acid, tris(tetramethylhydroxypiperidinol) citrate, a boswellic acid compound, and salts, isomers, derivatives, and mixtures of any of the foregoing; and a dermatologically acceptable carrier.


PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF

(WO2008062429) 29.05.2008 B82B 3/00 PANACEA BIOTEC LIMITED
The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.


COMPOSITION FOR REPELLING AND DETERRING VERMIN

(WO2008062006) 29.05.2008 A01N 25/02 NOVARTIS AG
The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I), as defined herein before. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of the formula (I) for the preparation of vermin-deterring compositions, and the use of compounds of formula (I) in the defense against vermin. Thus, the invention describes how and in which form the compounds of the formula (I) or their acid addition salts are used to deter vermin from materials, places or warm-blooded animals.


EXTERNAL COMPOSITION FOR SKIN CONTAINING MANASSANTIN B AS ACTIVE INGREDIENT AND THE USE THEREOF FOR SKIN WHITENING

(WO2008060056) 22.05.2008 A61K 31/343 AMOREPACIFIC CORPORATION
Disclosed herein are an external composition for skin, which contains, as an active ingredient, manassantin B extracted from Saururus chinensis Baill, and the use thereof for skin whitening. More particularly, disclosed are an external composition for skin, which contains, as an active ingredient, manassantin B, which inhibits the transfer of melanosomes, thus providing a skin-whitening effect without influencing the melanin synthesis function of the melanocytes, ad well as the use thereof for skin whitening.


TRANSDERMAL DELIVERY TECHNIQUES FOR DRUGS, NUTRACEUTICALS AND OTHER ACTIVE SUBSTANCES

(WO2008054788) 08.05.2008 A61K 9/70 CHRONO THERAPEUTICS, INC.
Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed dos...


SKIN EXTERNAL COMPOSITION CONTAINING CATHEPSIN G INHIBITORS FOR PREVENTING SKIN AGING AND THE SCREENING METHOD FOR DEVELOPMENT OF ANTIAGING MATERIALS

(WO2008054144) 08.05.2008 A61K 8/44 AMOREPACIFIC CORPORATION
Disclosed herein is a skin external composition for preventing skin aging, which contains a cathepsin G inhibitor as an active ingredient. Also disclosed is a method for screening anti-aging substances.


TOPICALLY APPLIED PROBUCOL-CONTAINING AGENT WITH PROTECTIVE AND REGENERATIVE EFFECT

(WO2008053374) 08.05.2008 A61K 8/46 NEUDECKER, Birgit
A method of treating skin changes and conditions in human skin including applying a topical preparation that includes an active agent including probucol, a derivative of probucol or a combination of probucol and a derivative of probucol.


ACNE TREATMENT

(WO2008053246) 08.05.2008 A61K 8/97 RECKITT & COLMAN (OVERSEAS) LIMITED
There is provided a method for the prophylactic or remedial treatment of acne, the method comprising the topical application of hydrolysed algin and at least one plant extract selected from Lavandula stoechas, Helichrysum italicum and Cistus monspeliensis. Also provided is a skincare composition comprising hydrolysed algin in combination with at least one plant extract selected from Lavandula stoechas, Helichrysum italicum and Cistus monspeliensis and a topical anti-acne active ingredient, preferably salicylic acid. The methods and compositions provide improved acne treatments, particularly in cosmetic effects such as reducing the redness of the affected area of skin.


COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS

(WO2008052326) 08.05.2008 A61K 35/56 SCALLOP SHELL POLLUTION SOLUTION LTD.
A composition for the treatment of various skin conditions where the composition comprises a solution which has been passed at least one time through a column containing a packing solid comprised of crushed mollusk shells of at least one size in diameter. This solution is then in admixture with a pharmaceutically acceptable carrier. This composition has effective applications as a cleaner and disinfectant and has also been found beneficial for the treatment of skin and other bodily diseases. Additionally, the shells can be pulverized and used as an active ingredient in the preparation of an ointment useful for medical treatments.


OINTMENT FOR CANCER TREATMENT

(WO2008052126) 02.05.2008 None UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
The invention provides an oil-based pharmaceutical composition comprising as an active ingredient phostphatidylserine or a derivative thereof and a pharmaceutically acceptable oil-based carrier, which is formulated for topical or intratumoral administration. Preferably, the composition is an ointmnent or a cream. The composition can contain additional active agents as well, such as aminophospholipid translocase inhibitors, transnitrosylating agents, chemokines, cytokines, Toll-like receptor ligands, imidazoquinolines, dendritic cell differentiation factors, or combinations thereof. In another aspect, the invention provides a method of treating cancer within a patient in need of treatment by administering the inventive composition to the pat...


2-HYDROXY-2-PHENYL/THIOPHENYL PROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS

(WO2008048540) 24.04.2008 A01N 43/54 MERCK & CO., INC.
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid- induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HFV-wasting, prostate cancer, benign prostatic h...


USE OF 1,2-DECANEDIOL FOR SEBUM REDUCTION AND COSMETIC AND/OR DERMATOLOGICAL FORMULATIONS COMPRISING 1,2-DECANEDIOL

(WO2008046791) 24.04.2008 A61K 8/34 SYMRISE GMBH & CO. KG
The present invention relates to a use of 1,2-decanediol for reduction of the sebum concentration of the skin, a cosmetic and/or dermatological formulation for topical application comprising 1,2-decanediol, a method for reduction of the sebum concentration of the skin and a use of 1,2-decanediol and a method for assisting the penetration of one, two, three, four or more active compounds into areas of the skin with increased sebum production.


LOW PH PHARMACOLOGICALLY ACTIVE PRODUCTS AND METHODS FOR THE PRODUCTION THEREOF

(WO2008045174) 17.04.2008 A01N 59/02 OMNIRELIANT HOLDINGS INC., A Corporation of the state of Nevada
There is provided a new technology that will allow the formulation of pharmaceutically active organic acid products at relatively high pH during storage. This affords the advantages of avoiding formulation with the acid form of the product, yet when the product is used, the pH will be reduced via a chemical reaction, thus forming the organic acid which is the active form of the product. A by-product of the reaction is a significant increase in temperature, thus adding to the efficacy of the organic acid.


METHOD FOR PREPARING KAEMPFEROL-3-0-RUTINOSIDE AND COMPOSITION OF SKIN EXTERNAL APPLICATION COMPRISING THEREOF

(WO2008044818) 17.04.2008 C12P 19/44 AMOREPACIFIC CORPORATION
The present invention relates to a method for the preparation of kaempferol-3- O-rutinoside and a composition of a skin external application comprising kaempferol-3- O-rutinoside as an active ingredient. In particular, the present invention relates to a method for isolating kaempferol-3-O-rutinoside through hydrolysis using an enzyme or microbe that removes the sugar selectively from kaempferol-3-O-rutinoside glycosides in a plant extract, and a composition of a skin external application comprising kaempferol-3-O-rutinoside that prevents skin wrinkle.


NEW COMPOSITION FOR IMPROVING SKIN QUALITY AND A PROCESS FOR PREPARING THE SAME

(WO2008043856) 17.04.2008 A23L 1/30 COMPAGNIE GERVAIS DANONE
The present invention relates to a composition comprising, as active substance, a mixture of at least one polyunsaturated fatty acid, different from polyunsaturated fatty acid derived from milk, polyphenols, milk proteins and lactic bacteria, and said composition having a water content of at least 50% by weight; and wherein the said polyunsaturated fatty acid presents an increased bioavailability compared with the one of the polyunsaturated fatty acid alone.


ELECTROKINETIC SYSTEM AND METHOD FOR DELIVERING METHOTREXATE

(WO2008042404) 10.04.2008 A61N 1/30 TRANSPORT PHARMACEUTICALS, INC.
The electrokinetic methotrexate delivery system includes at least one applicator having a multiplicity of non-conductive micro-needles carried on a non-conductive surface of the applicator. The opposite surface is formed of electrically conductive material for contact with an active electrode. The applicator includes a matrix containing a medicament, e.g., methotrexate, or a carrier therefor between the opposite surfaces. When the applicator is applied to the individual's skin with the micro-needles penetrating the skin, an electrical current is completed through the power source, the active electrode, methotrexate, or electrically conductive carrier therefor, the targeted treatment site, the individual's body, a ground electrode and the po...


PHOTOPROTECTIVE COMPOSITIONS COMPRISING SYNERGISTIC COMBINATION OF SUNSCREEN ACTIVE COMPOUNDS

(WO2008042326) 10.04.2008 A61K 8/37 SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC.
Compositions for topical application to skin and/or hair, comprising photoprotecting synergistically effective amounts of sunscreen active agents octinoxate, octocrylene, and amiloxate; methods of protecting skin and/or hair against deleterious effects of sunlight/UV radiation by topical application of compositions.


METHOD OF WOUND/BURN HEALING USING COPPER-ZINC COMPOSITIONS

(WO2008042197) 10.04.2008 A61K 33/30 JR CHEM, LLC
Composition and methods for alleviating or eliminating wounds and/burns by providing an effective amount of one or more copper, zinc and copper-zinc compositions are disclosed. Treatment is accomplished through the use of topical compositions containing one or more copper or zinc salts and/or copper-zinc compounds or complexes, particularly copper-zinc malonate active ingredient.


A MULTI CHAMBER CONTAINER FOR THE PRODUCTION AND DISPENSING OF CARBON DIOXIDE FOAM, PROCESS FOR PRODUCTION AND USE OF SAID FOAM

(WO2008041045) 10.04.2008 A61K 8/04 PILLER, István
The invention relates to a filled two-compartment container providing carbon dioxide foam. The invention is characterized in that one compartment (3) contains an acid, and the other compartment (4) contains a carbonate or hydrogen carbonate. Further, it also contains (in at least one of the compartments (3)) a surface-active (detergent) material, cosmetic base materials, water and optionally 'pharmacons' where the release of the ingredients is aided through the dosing equipment (5) to a given surface, preferably to the skin. The invention also relates to process for preparing foam composition containing carbon dioxide gas.


EMULSION FORMULATIONS FOR TRANSDERMAL DELIVERY OF POORLY WATER SOLUBLE ACTIVE AGENTS

(WO2008039864) 03.04.2008 A61K 9/06 NOVAVAX, INC.
A composition for transdermal delivery of a non- traditional active agent is described. The compositions comprise: (a) a non-traditional transdermal active agent; (b) a solvent; (c) a non-miscible liquid; (d) a stabilizer; and (e) water, wherein the composition is formulated into an emulsion.


MARINE EXTRACTS AND BIOFERMENTATIONS FOR USE IN COSMETICS

(WO2008039515) 03.04.2008 A61K 8/97 BASF BEAUTY CARE SOLUTIONS LLC
An extract of the marine algae, Sarcodiotheca, and more particularly Sarcodiotheca gaudichaudii, is described for use in cosmetic compositions. A biofermentation of Sarcodiotheca, such as for example S. gaudichaudii, is also described. This marine bioferment is useful as a skin care active ingredient for anti-aging cosmetic applications, and particularly useful when used in combination with an extracts of red algae, such as Chondrus crispus.


MODIFIED SELF-ASSEMBLING PEPTIDES

(WO2008039483) 03.04.2008 C07K 7/00 MASSACHUSETTS INSTITUTE OF TECHNOLOGY
The present invention provides a self-assembling peptide comprising: (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain that does not mediate self- assembly in isolated form, wherein the second amino acid domain comprises at least one minimal biologically active sequence. Such self-assembling peptides are described herein as 'modified self-assembling peptides.' The present invention also provides pharmaceutical compositions, kits and maxtrices comprising a modified self-assembling peptide, ...


FOAMABLE VEHICLE COMPRISING DICARBOXYLIC ACID OR DICARBOXYLIC ACID ESTER AND PHARMACEUTICAL COMPOSITIONS THEREOF

(WO2008038147) 03.04.2008 A61K 9/12 FOAMIX LTD.
The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a...


A DOUBLE STRANDED RNA OLIGONUCLEOTIDE: A PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING IT AND ITS USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT IN THE TREATMENT OF ANDROGEN-RELATED DISEASES

(WO2008035291) 27.03.2008 None PABLO CASSARA DO BRASIL, COMERCIO DE MEDICAMENTOS LTDA.
This invention refers to new double stranded oligonucleotides having specific antiandrogenic activity and particularly to their use in the treatment of androgen-related diseases. Oligonucleotides may preferably be formulated with an acceptable pharmaceutical support in pharmaceutical or cosmetic formulations which are related to androgen metabolism or aimed at providing a beneficial effect on skin and/or hair.


COSMETIC USE OF ACTIVE AGENTS THAT STIMULATE MATRIPTASE EXPRESSION

(WO2008034821) 27.03.2008 A61K 8/97 CHANEL PARFUMS BEAUTE
The present invention relates to a cosmetic process for caring for human skin, intended to moisturize it and/or to protect it against drying out, comprising the topical application to the skin of a composition containing at least one active agent that stimulates the expression of the matriptase MT/SP1. It also relates to the cosmetic use of such an active agent for moisturizing human skin and/or protecting it against drying out. It further relates to the use of such an active agent to manufacture a pharmaceutical composition intended to prevent and/or alleviate skin tautness, stinging and/or itching and/or lip chapping. The active agents are extracts of Ceratonia siliqua, Cananga odorata hook, Cedrelopsis grevei and Cistus ladaniferus L..


EMULSION

(WO2008034447) 27.03.2008 A61K 8/04 Riemann Trading ApS
The present invention pertains to a novel emulsion-type product. In particular, the product may be in the form of a sunscreen product or a cosmetic. The invention further provides a method for producing said product, as well as a formulation comprising the emulsion-type product and an active ingredient. Further aspects of the invention include the use of said emulsion-type product in combination with at least one sunscreen agent as a sunscreen product.


COLORED OR COLORABLE FOAMABLE COMPOSITION AND FOAM

(WO2008032212) 20.03.2008 A61K 31/47 FOAMIX LTD.
There is described a colored or colorable topical composition, comprising: a) a foamable base composition comprising, 1 ) a flowable carrier composition; 2) a color agent; wherein the color agent is effective to impart, increase, decrease or otherwise affect color of a foam produced from the foamable composition and wherein the color agent is one or more agents selected from the group consisting of a colored active agent, a colored indicator, a colored excipient, a pigment, a dye, a colorant and a coloring agent; b) a propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the base composition has a first color; and wherein the foam comprising the colored or colorable topical composition has a seco...


PERSONAL CARE COMPOSITIONS COMPRISING PEAR SEED EXTRACT

(WO2008027533) 06.03.2008 A61K 8/97 THE PROCTER & GAMBLE COMPANY
Personal care compositions comprising pear seed extract as the active component, use of such compositions for regulating the condition of mammalian keratinous tissue. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.


USE OF A COMBINATION OF METHOTREXATE AND AN A3AR AGONIST FOR THE TREATMENT OF CANCER

(WO2008023362) 28.02.2008 A61K 31/519 CAN-FITE BIOPHARMA LTD.
The therapeutic treatment of cancer by a combined administration of methotrexate and an agonist of the A3 adenosine receptor. Provided are pharmaceutical compositions comprising such a combined administration useful in the therapeutic treatment of cancer as well as the use of any of these active agents for preparing such a pharmaceutical composition.


TOPICAL FORMULATION OF MULTILAMELLAR VESICLES COMPOSITION FOR PERCUTANEOUS ABSORPTION OF PHARMACEUTICALLY ACTIVE AGENT

(WO2008021847) 21.02.2008 A61K 9/127 MCGRAW, Thomas
A composition of multilamellar vesicles for the delivery of pharmaceutically-active substances through the skin of a mammal, the composition including between about 1 to about 30% Cyclomethicone 5-.N.F., between about 1 to about 30% PEG-12 Dimethicone; between about 3 to about 14% Cyclopentasiloxane and PEG 12 Dimethicone Crosspolymers, between about 0.9 to about 9% Lauryl PEG/PPG - 18/18 Methicone, between about 2 to 5% Sepigel 305, between about 1 to about 4%, Carbopol ETD 2020 solution (2%), up to 100% Water, and Sodium hydroxide to a pH between about 6-6.5.


SEMI-FINISHED PRODUCT IN THE MANUFACTURE OF A COMPOSITION FOR SKIN OR HAIR CARE

(WO2008020112) 21.02.2008 A61K 8/34 OY GRANULA AB LTD
The invention relates to a semi-finished product, which is manufactured from raw liquid, raw extract or raw powder obtained from wood material, an end product composition for skin or hair care being obtained from the semi-finished product by adding one or more components thereto. The semi-finished product optionally contains a UV protector, and it is a liquid, such as solution, emulsion, microemulsion or nanoemulsion or a semi-solid substance, such as dispersion, suspension, wax, lotion or gel or a solid substance, and the skin or hair care composition (the end product) can be manufactured from the semi-finished product by adding liquid thereto. The semi-finished product further contains an active ingredient mixture, which is obtained from ...


ALPHA LIPOIC ACID COMBINED WITH DIMETHYLSULFOXIDE FOR TROPICAL USE

(WO2008018106) 14.02.2008 A61K 31/385 RIVER PHARMA SRL
The present invention has as its object a new pharmaceutical or cosmetic composition containing as active ingredients an antioxidant agent with molecular weight of between 100 Da and 300 Da and dimethylsulfoxide, capable of improving the absorption, the bioavailability and the effectiveness in formulations for topical use.


NANOLIPOSOME USING ESTERIFIED LECITHIN AND METHOD FOR PREPARING THE SAME, AND COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING THE SAME

(WO2008016258) 07.02.2008 A61K 9/127 DAEWOONG CO., LTD.
The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereb...


TOPICAL PREPARATION CONTAINING SIROLIMUS FOR TREATING INFLAMMATORY SKIN DESEASES

(WO2008015539) 07.02.2008 A61K 47/06 AHUMADA AYALA, Fernando
The present invention relates to a topical preparation for treating inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), in an ointment form containing sirolimus as active ingredient and a carrier formulated with all or some of the following components: ultra white petrolatum, mineral oil, glyceryl monostearate, anhydrous lanoline, white wax, N-methyl-2-pyrrolidone and antioxidant. The advantages of the present invention with respect to the state of the art compositions are based on the fact that the present composition contains an immunosupressing macrolide which acts specifically binding to a family of cytosolic immunophylins known as FKBP thus offering fewer adverse effects, compared to other agents used ...


NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT

(WO2008014979) 07.02.2008 C12N 15/11 CUREVAC GMBH
The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substa...


DELIVERY SYSTEM AND METHOD OF MANUFACTURING THE SAME

(WO2008013757) 31.01.2008 A61K 8/04 AMCOL INTERNATIONAL CORPORATION
A microparticle delivery system for an active compound which includes an active compound loaded onto polymeric microparticles, wherein the loaded microparticles are encased by a matrix material comprising about 68% to about 99%, by weight, of the microparticle delivery system. Compositions containing the microparticle delivery system, and methods of manufacturing the microparticle delivery system, also are disclosed.


COSMETIC COMPOSITION FOR EXFOLIATING SKIN KERATIN

(WO2008013342) 31.01.2008 A61K 8/66 AMOREPACIFIC CORPORATION
The present invention relates to a cosmetic composition containing enzymes, and more particularly to a cosmetic composition, which contains, as active ingredients, 1) papain, and 2) at least one selected from the group consisting of theanine and N-acetyl glucosamine, and thus functions to control the skin turnover cycle and promote the exfoliation of skin keratin.


IMMUNE RESPONSE MODIFIER FORMULATIONS

(WO2008010963) 24.01.2008 A61K 31/4745 3M INNOVATIVE PROPERTIES COMPANY
The present invention provides a pharmaceutical foam formulation. Generally, the formulation includes a therapeutically effective amount of imiquimod and a fatty acid.


TREATMENT ARTICLES CAPABLE OF DELIVERING INTENSIVE CARE AND OVERALL TREATMENT SIMULTANEOUSLY

(WO2008010167) 24.01.2008 A61Q 19/00 THE PROCTER & GAMBLE COMPANY
The present invention relates to treatment articles capable of delivering intensive care and overall care simultaneously. The articles comprise a first substrate, a second substrate which substantially covers the first substrate at-use, a first treatment composition and a second treatment composition wherein the delivery of the skin care active to the skin is initiated by the treatment composition. The articles also comprise a first substrate which contains a first treatment composition, a second substrate which substantially cover the first substrate at-use and a treatment composition wherein delivery of the first treatment composition is initiated by the second treatment composition. Preferred articles of the present invention comprise fa...


FATTY ACID PHARMACEUTICAL FOAM

(WO2008008397) 17.01.2008 C08J 9/00 STIEFEL RESEARCH AUSTRALIA PTY LTD
The present invention provides a foamable composition comprising water and an organic solvent, wherein the organic solvent comprises a fatty acid. The composition may further comprise a pharmaceutically active agent. The composition of the invention is also useful for the treatment of a dermatological disorder in a mammal by the topical administration of the composition.


COMPOSITIONS COMPRISING ROSEHIP AND OTHER ACTIVE AGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

(WO2008006589) 17.01.2008 A61P 29/00 DSM IP ASSETS B.V.
The present invention relates to novel compositions comprising rosehip and at least one additional component e.g. selected from ligustilide, oleuropein (I), oleuropein aglycone (II), hydroxytyrosol, genistein, magnolol, honokiol, magnolia bark extract, cashew fruit extract and Glycyrrhiza foetida as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.


COMPOSITIONS COMPRISING MAGNOLOL OR HONOKIOL AND OTHER ACTIVE AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES

(WO2008006582) 17.01.2008 A61K 36/575 DSM IP ASSETS B.V.
The present invention relates to novel compositions comprising magnolol and/ or honokiol and at least one additional component e.g. selected from ligustilide, oleuropein (I), oleuropein aglycone (II), hydroxytyrosol, rosehip, genistein, resveratrol, EGCG, cashew fruit extract and Glycyrrhiza foetida as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders.


ANTIMICROBIAL PEPTIDE DERIVED FROM GALANIN MESSAGE ASSOCIATED PEPTIDE (GMAP)

(WO2008006467) 17.01.2008 C07K 14/575 AUSTRIA WIRTSCHAFTSSERVICE GESELLSCHAFT MBH
The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases.


USE OF C-GLYCOSIDE DERIVATIVES AS PRO-DESQUAMATING ACTIVE AGENTS

(WO2008004165) 10.01.2008 A61K 8/60 L'OREAL
The present invention relates to a cosmetic use of at least one C-glycoside derivative in a composition comprising a physiologically acceptable medium, as a cosmetic agent for promoting the desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal.


AN ANTI-VIRAL COMPOSITION FOR THE TOPICAL TREATMENT OF HERPES LABIALIS (COLD SORES) AND METHOD FOR USE THEREOF

(WO2008002777) 03.01.2008 A61K 31/555 REDOX PHARMACEUTICAL CORPORATION
A composition for the treatment of Herpes Labialis which contains CTC-96 as the active ingredient is disclosed. Methods for using the composition are also disclosed. The composition may be used as a topical ointment.


FUNCTIONAL COMPOSITIONS CONTAINING CATIONIC HYDROPHOBICALLY MODIFIED POLYSACCHARIDES FOR PERSONAL CARE, HOUSEHOLD & INSTITUTIONAL AND PET CARE PRODUCTS

(WO2008002666) 03.01.2008 A61K 8/73 HERCULES INCORPORATED
This invention relates to functional compositions for use in personal care, household & institutional and pet care applications and which contain cationic hydrophobically modified polysaccharides thereby permitting a reduction in the amount of active ingredient material present in the functional composition over amounts typically found in conventional functional compositions while substantially maintaining the level of performance of the functional composition when compared to the level of performance of the conventional functional composition.


TWO-PHASE MUCOADHESIVE COMPOSITION

(WO2008002353) 03.01.2008 A61K 9/14 DOW PHARMACEUTICAL SCIENCES
A novel two-phase, film-forming, mucoadhesive gel composition has been developed. The composition contains an anhydrous non-aqueous solvent, a water-insoluble polymer that is dissolved in the non-aqueous solvent, and a water- soluble polymer that is dispersed in the non-aqueous solvent. The composition adheres to water-bearing surfaces, such as to moistened skin or mucosal surfaces, and can be used to provide extended, local delivery of pharmaceutically active agents from the composition to skin or a mucosal surface. The composition may be solvent-cast to form a mucoadhesive film, which may contain a polymeric backing layer. The mucoadhesive film may further contain a pharmaceutically active agent and may be used to administer the pharmaceu...


UNSATURATED ALKYL ESTERS OF 5-AMINOLEVULINIC ACID, THEIR PREPARATION AND THEIR USE

(WO2008002087) 03.01.2008 C07C 229/22 INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
Disclosed are unsaturated alkyl esters of 5- aminovulinic acid of the following chemical formula 1, or pharmaceutically acceptable salts thereof, a method for preparing the same, and uses thereof. [Chemical Formula I] NH2-CH2-CO-CH2-CH2-CO-O-R wherein, R is a group selected from a group consisting of 2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, cis-2-pentenyl, cis-3-hexenyl, cis-4-hexenyl, and trans-2-hexenyl. Also, a pharmaceutical composition comprising the unsaturated alkyl ester of 5-aminovulinic acid or a salt thereof as an active ingredient is provided. This pharmaceutical composition is easily absorbed transdermally and is of low cytotoxicity. Featuring no amino -protecting processes, the method guarantees high production yields.


TRANSDERMAL COMPOSITIONS OF PRAMIPEXOLE HAVING ENHANCED PERMEATION PROPERTIES

(WO2008001204) 03.01.2008 A61K 9/70 ANTARES PHARMA IPL AG
A pharmaceutical composition for transdermal or transmucosal delivery of an active agent to treat a movement disorder such as Parkinson's disease. The composition provides enhanced transdermal or transmucosal delivery of the active agent by including an alkanolamine as a permeation enhancer with a carrier of water and at least one short-chain alcohol and with the composition having a neutral pH. The composition provides controlled and sustained release of the active agent suitable for daily administration.


COMPOSITION FOR THE TREATMENT OF SKIN COMPRISING INK SACK LIQUID OF CEPHALOPODS

(WO2008000454) 03.01.2008 A61P 31/10 ISDIN
The present invention relates to a composition comprising as active mixture ink sack liquid, preferably the natural ink sack liquid of cephalopods and optionally further components of cephaiopods, the use of said liquid to prepare a drug tor the prophylaxis and/or treatment of mycosis, preferably onychomycosis and other pathological skin conditions, and to the use of such composition as a cosmetical composition.

World  Patents Published  in 2009
 
World Patents Published in 2007
PCT -  World Patents in Skin Care Actives Published in 2008
...or use our Search Engine
to search for patent
documents by number.
Search for anything.
Simply type the words in
the box..
Clck to enlarge and view details
WORLD PATENTS IN ACTIVES FOR SKIN CARE GRANTED IN  2008
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications
published. Salient search terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening,
blemish removal, etc. This category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavenger, "green"
derived molecules, etc.